Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Panacea Acquisition Corp | NUVB | NYSE | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.61 | 03:05:14 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.61 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.95 - 4.1598 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 2.61 | USD |
Panacea Acquisition Corp Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 571.71M | 219.05M | - | 0 | -75.8M | -0.35 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Panacea Acquisition News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NUVB Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.91 | 3.2199 | 2.58 | 2.96 | 1,953,556 | -0.30 | -10.31% |
| 1 Month | 3.19 | 3.55 | 2.58 | 3.15 | 1,314,417 | -0.58 | -18.18% |
| 3 Months | 2.33 | 4.1598 | 1.67 | 3.10 | 1,668,861 | 0.28 | 12.02% |
| 6 Months | 1.34 | 4.1598 | 1.27 | 2.64 | 1,156,760 | 1.27 | 94.78% |
| 1 Year | 1.68 | 4.1598 | 0.95 | 2.05 | 1,058,883 | 0.93 | 55.36% |
| 3 Years | 12.36 | 13.63 | 0.95 | 4.01 | 900,176 | -9.75 | -78.88% |
| 5 Years | 10.00 | 15.23 | 0.95 | 4.76 | 896,888 | -7.39 | -73.90% |
Panacea Acquisition Description
| Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. |
